PL2992020T3 - Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1 - Google Patents

Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1

Info

Publication number
PL2992020T3
PL2992020T3 PL14791494T PL14791494T PL2992020T3 PL 2992020 T3 PL2992020 T3 PL 2992020T3 PL 14791494 T PL14791494 T PL 14791494T PL 14791494 T PL14791494 T PL 14791494T PL 2992020 T3 PL2992020 T3 PL 2992020T3
Authority
PL
Poland
Prior art keywords
effector cells
antigen receptor
chimeric antigen
immune effector
engineered immune
Prior art date
Application number
PL14791494T
Other languages
English (en)
Inventor
Jianhua Yu
Craig HOFMEISTER
Jianhong CHU
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of PL2992020T3 publication Critical patent/PL2992020T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
PL14791494T 2013-05-03 2014-05-02 Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1 PL2992020T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361819141P 2013-05-03 2013-05-03
US201361876492P 2013-09-11 2013-09-11
PCT/US2014/036684 WO2014179759A1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells
EP14791494.9A EP2992020B1 (en) 2013-05-03 2014-05-02 Cs1-specific chimeric antigen receptor engineered immune effector cells

Publications (1)

Publication Number Publication Date
PL2992020T3 true PL2992020T3 (pl) 2020-06-01

Family

ID=51844005

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14791494T PL2992020T3 (pl) 2013-05-03 2014-05-02 Odpornościowe komórki efektorowe wyrażające inżynierowane chimeryczne receptory antygenu swoiste dla CS1

Country Status (15)

Country Link
US (3) US10358494B2 (pl)
EP (2) EP2992020B1 (pl)
JP (3) JP6856188B2 (pl)
KR (1) KR102098985B1 (pl)
CN (2) CN105377897A (pl)
AU (2) AU2014259675B2 (pl)
BR (1) BR112015027567B1 (pl)
DK (1) DK2992020T3 (pl)
ES (1) ES2777940T3 (pl)
HU (1) HUE048312T2 (pl)
IL (1) IL242315B (pl)
MX (1) MX370173B (pl)
PL (1) PL2992020T3 (pl)
PT (1) PT2992020T (pl)
WO (1) WO2014179759A1 (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CN107429253B (zh) * 2014-12-05 2021-11-05 希望之城公司 Cs1靶向性嵌合抗原受体修饰的t细胞
HK1246180A1 (zh) * 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
CN108367057B (zh) 2015-04-06 2022-11-22 赛通免疫股份有限公司 用于胶质母细胞瘤的egfr导向的car疗法
TW201706300A (zh) * 2015-05-20 2017-02-16 瑟勒提斯公司 用於癌症免疫療法之抗－ｇｄ３專一性嵌合抗原受體
ES2958720T3 (es) * 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
KR102157701B1 (ko) 2015-08-17 2020-09-21 서울대학교산학협력단 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
EP4289944A3 (en) * 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
KR20180101540A (ko) * 2016-01-15 2018-09-12 이투빅스 코포레이션 T 세포 면역요법을 위한 방법 및 조성물
US11090334B2 (en) 2016-01-29 2021-08-17 Med Manor Organics (P) Ltd. Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
US11365237B2 (en) 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
CN109414512A (zh) 2016-04-22 2019-03-01 科济生物医药（上海）有限公司 用于细胞免疫疗法的组合物和方法
US12516292B2 (en) 2016-07-25 2026-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing modified natural killer cells and methods of use
EP3487991B1 (en) 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
CN106279432B (zh) * 2016-08-10 2019-09-20 深圳市再生之城生物医药技术有限公司 一种vc-car分子及在清除hiv-1感染细胞中的应用
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
BR112019012950A2 (pt) 2016-12-23 2019-11-26 Macrogenics, Inc. molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
CN110475857B (zh) 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
WO2018175453A1 (en) * 2017-03-20 2018-09-27 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells for treatment of al amyloidosis
CN110636855B (zh) * 2017-03-28 2024-08-09 俄亥俄州创新基金会 人pd1肽疫苗及其用途
WO2018189360A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
CN111212663A (zh) * 2017-07-07 2020-05-29 H·李·莫菲特癌症中心研究所公司 具有突变的cd28共刺激性结构域的嵌合抗原受体
EP3652203B1 (en) * 2017-07-14 2025-07-02 The Johns Hopkins University Engineered tsc2
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
WO2019069125A1 (en) * 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
US20200283501A1 (en) 2017-10-26 2020-09-10 Regents Of The University Of Minnesota Recombinant immune cells, methods of making, and methods of use
US12077598B2 (en) 2018-03-16 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 phosphorylation sites
CA3103610A1 (en) 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
WO2020010341A1 (en) * 2018-07-05 2020-01-09 Emory University Transduction of innate immunocompetent cells using aav6
CN112469734A (zh) * 2018-08-03 2021-03-09 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
CA3111384A1 (en) * 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
EP4332115A3 (en) 2019-04-03 2024-05-29 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
EP4054602A4 (en) * 2019-11-08 2023-12-06 Mayo Foundation for Medical Education and Research EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS
US12703750B2 (en) 2020-04-11 2026-08-11 Northwestern University Humanized antibody targeting the tumor associated antigen IL13Ra2
US20230242641A1 (en) * 2020-06-29 2023-08-03 Julius-Maximilians-Universität Würzburg Slamf7 cars
CN114286691B (zh) * 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 Cs1-抗体和抗cs1-car-t细胞
WO2022063302A1 (zh) * 2020-09-25 2022-03-31 克莱格医学有限公司 免疫细胞活性调节
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
EP4626924A4 (en) * 2022-12-02 2026-07-15 Guangzhou Litai Biotechnology Co Ltd Human cs1 car-t cells
US20260001951A1 (en) * 2024-06-28 2026-01-01 Immunitybio, Inc. Anti-SLAMF7 Antibodies And Therapeutics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
EP1266014A2 (en) * 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
JP2012507555A (ja) 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション 稀少疾患の治療における抗ｃｓ１抗体の使用
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2556085A2 (en) 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
EP3115373B1 (en) * 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
CA2818684C (en) * 2010-11-22 2023-02-21 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6053688B2 (ja) * 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
AU2012340174A1 (en) 2011-11-16 2014-05-29 Amgen Inc. Methods of treating epidermal growth factor deletion mutant VIII related disorders
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP2929032A4 (en) 2012-12-07 2016-04-06 Solazyme Inc GENETICALLY MODIFIED MICROBIAL STRAINS WITH CHLORELLA PROTOTHECOIDES LIPID SIGNAL PROGRAMS
CN103224561A (zh) 2013-01-16 2013-07-31 天津大学 葡萄球菌肠毒素小分子抗体及制备方法及用途
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
KR20200131844A (ko) * 2018-03-16 2020-11-24 사이토이뮨 테라퓨틱스 인코퍼레이티드 이중특이적 항체 car 세포 면역요법

Also Published As

Publication number Publication date
MX2015015182A (es) 2016-05-05
CN115028735A (zh) 2022-09-09
IL242315B (en) 2020-07-30
AU2014259675B2 (en) 2019-05-02
BR112015027567B1 (pt) 2024-02-20
CN105377897A (zh) 2016-03-02
AU2014259675A1 (en) 2015-11-12
EP3663320A1 (en) 2020-06-10
US10358494B2 (en) 2019-07-23
US10227409B2 (en) 2019-03-12
AU2019203823A1 (en) 2019-06-20
PT2992020T (pt) 2020-02-28
US20200002418A1 (en) 2020-01-02
ES2777940T3 (es) 2020-08-06
DK2992020T3 (da) 2020-02-10
KR102098985B1 (ko) 2020-04-09
US20170320941A1 (en) 2017-11-09
EP2992020B1 (en) 2020-01-15
MX370173B (es) 2019-12-04
EP2992020A4 (en) 2016-12-28
US20160075784A1 (en) 2016-03-17
AU2019203823B2 (en) 2021-05-13
US11845794B2 (en) 2023-12-19
WO2014179759A1 (en) 2014-11-06
JP6856188B2 (ja) 2021-04-07
JP2016524598A (ja) 2016-08-18
BR112015027567A2 (pt) 2017-12-05
JP2019146579A (ja) 2019-09-05
CA2910666A1 (en) 2014-11-06
HUE048312T2 (hu) 2020-07-28
JP7221338B2 (ja) 2023-02-13
EP2992020A1 (en) 2016-03-09
HK1218925A1 (en) 2017-03-17
JP2021177771A (ja) 2021-11-18
KR20160003071A (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
IL242315B (en) Transgenic immune activator cells of chimeric antigen receptor specific for cs1
IL290459A (en) Modified t cells - targeted chimeric antigen receptor cs1
IL273785A (en) Immune response prediction of t-cell epitopes
IL244784A0 (en) chimeric antigen receptor
IL269538B1 (en) Universal anti–cd22 chimeric antigen receptor transgenic immune cells
EP3087101A4 (en) Regulatable chimeric antigen receptor
EP3057991B8 (en) Chimeric antigen receptor t cell switches and uses thereof
IL239500A0 (en) Chimeric antigen receptors
SG10201708896WA (en) Cd19 specific chimeric antigen receptor and uses thereof
IL237576B (en) Multichain chimeric antigen receptor and its uses
EP3057994A4 (en) Peptidic chimeric antigen receptor t cell switches and uses thereof
PL3114147T3 (pl) Chimeryczny receptor antygenowy
SG11201504765VA (en) Anti-h7cr antibodies
GB201312226D0 (en) Improved antibodies
PT2821416T (pt) Anticorpo de recetor il-23 anti- humano inovador
ZA201508068B (en) Cd19 specific chimeric antigen receptor and uses thereof
GB201409761D0 (en) Chimeric antigen receptor
GB201310565D0 (en) Antigen immunogenicity characterisation assay